Providers

Latest News

While the findings suggest that switching to onasemnogene abeparvovec after non–gene therapy treatments could be beneficial to patients with spinal muscular atrophy, it is not clear which patients may benefit the most from switching therapies. | Image credit: Rochu_2008 - stock.adobe.com
Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA

August 15th 2025

Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.

Paper saying Medicaid eligibility | Image credit: Vitalii Vodolazskyi – stock.adobe.com
5 Key Takeaways on Medicaid Policy Changes From Savista’s Chief Strategy Officer

August 15th 2025

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

Myasthenia Gravis | Image Credit: © Richelle - stock.adobe.com
Even Low Disease Activity Has QOL Impact in Myasthenia Gravis

August 14th 2025

The researchers noted diabetes and hypertension are both modifiable with appropriate management that brings patients to guidelines-based targets. | Image Credit: Crystal light - stock.adobe.com
PCPs Have Unique Opportunity to Detect, Manage CKD

August 14th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo